

HIPAA/SAMHSA CONFIDENTIALITY POLICY

SCOPE: This policy applies to LAKEVIEW HOLDINGS and all of its Affiliates

PURPOSE: To establish the requirements for LAKEVIEW HOLDINGS to meet confidentiality standards and utilize patient authorizations to use or disclose Covered Information as required by the Standards for Confidentiality of Substance Use Disorder Patient Records (42 CFR Part 2). The Health Insurance Portability and Accountability Act of 1996 and the regulations promulgated in connection therewith (“HIPAA”) establish certain minimum standards for protection of patient health information, but 42 U.S.C. § 290dd-2, 42 U.S.C. § 290ee-3 and regulations under 42 CFR Part 2 apply additional requirements for use and disclosure of records relating to substance use disorders for Lakeview Holdings. The purpose of this Policy is to set forth certain special terms that apply to the use and disclosure of Covered Information (as described below) relating to individuals that have a substance use disorder.

POLICY: Records of the identity, diagnosis, prognosis, or treatment of any Patient relating to a substance use disorder which are maintained in connection with Lakeview Holdings, or which are received from Lakeview Holdings Program will be confidential and may be disclosed only as expressly permitted pursuant to this Policy. Notwithstanding any provision in the Lakeview Holdings policies to the contrary, for records maintained by or received from a Lakeview Holdings Program identifying Patients as having a substance use disorder, the records may only be disclosed to the extent specifically permitted pursuant to 42 CFR Part 2.

DEFINITIONS:

Affiliate means any person or entity Controlling, Controlled by or under common Control with another person or entity.

Control means the direct or indirect power to govern the management and policies of an entity; or the power or authority through a management agreement or otherwise to approve an entity's transactions (includes Controlled, Controlling).

Covered Information means any information, whether recorded or not, created by, received, or acquired by a Lakeview Holdings relating to a Covered Patient (e.g., Diagnosis, Treatment and referral for Treatment information, billing information, emails, voice mails, and texts). For the purpose of this Policy, Covered Information includes both paper and electronic records. Covered Information includes, without limitation, medical records maintained by Lakeview Holdings or obtained from a Lakeview Holdings Program identifying an individual as Patient.

Patient(s) means any individual who has applied for or been given Diagnosis, Treatment, or referral for Treatment for a Substance Use Disorder at a Lakeview Holdings. The term Covered Patient includes any individual who, after arrest on a criminal charge, is identified as an individual with a Substance Use Disorder in order to determine that individual's eligibility to participate in Lakeview Holdings Program. This definition includes both current and former patients. The special restrictions of this Policy apply to the use and Disclosure of information identifying an individual as a Patient.

Diagnosis means any reference to an individual's Substance Use Disorder or to a condition which is identified as having been caused by that Substance Use Disorder which is made for the purpose of Treatment or referral for Treatment.

Disclose or Disclosure means to communicate any information identifying a patient as being or having been diagnosed with a Substance Use Disorder, having or having had a Substance Use Disorder, or being or having been referred for Treatment of a Substance Use Disorder either directly, by reference to publicly available information, or through verification of such identification by another person.

General Designation Disclosure means a Disclosure made pursuant to a consent or authorization for Disclosure, where the consent or authorization identifies the recipient of the Covered Information with a general designation, rather than by the name of the entity or individual receiving the Covered Information. Disclosures to healthcare providers pursuant to Attachment B, Consent for Disclosure of Information for Treatment and Billing/Payment, where the name of the healthcare provider receiving the information is not listed, will be considered a General Designation Disclosure. Disclosures to Qualified Service Organizations generally will not be considered General Designation Disclosures. Disclosures made to an entity or individual specifically identified by name on a consent for Disclosure are not considered General Designation Disclosures.

Maintenance Treatment means long-term pharmacotherapy for individuals with Substance Use Disorders that reduces the pathological pursuit of reward and/or relief and supports remission of Substance Use Disorder-related symptoms.

Patient Identifying Information means the name, address, social security number, fingerprints, photograph, or similar information by which the identity of a Patient can be determined with reasonable accuracy either directly or by reference to other information. The term does not include a number assigned to a Patient by Lakeview Holdings, for internal use only by the Lakeview Holdings, if that number does not consist of or contain numbers (such as a social security, or driver's license number) that could be used to identify a Patient with reasonable accuracy from sources external to Lakeview Holdings.

Program Director means the individual designated as the "Program Director" for the relevant Lakeview Holdings. For purposes of this policy, a Program Director may be the Chief Executive Officer of a free-standing behavioral health hospital, a Director of an inpatient behavioral health unit, or a Director or Manager of an outpatient behavioral health program.

Qualified Service Organization means an individual or entity who: (a) provides services to Lakeview Holdings, such as data processing, bill collecting, dosage preparation, laboratory analyses, or legal, accounting, population health management, medical staffing, or other professional services, or services to prevent or treat child abuse or neglect, including training on nutrition and child care and individual and group therapy, and (b) has entered into a written agreement with Lakeview Holdings under which that individual or entity: (i) acknowledges that in receiving, storing, processing, or otherwise dealing with any patient records from Lakeview Holdings, it is fully bound by the regulations in this part;

and (ii) if necessary, will resist in judicial proceedings any efforts to obtain access to Patient Identifying Information related to Substance Use Disorder Diagnosis, Treatment, or referral for Treatment except as permitted by 42 CFR Part 2. A business associate agreement that includes the terms referenced above through execution of the Substance Use Disorder Patient Information Addendum or other written agreement approved by the Privacy Official may satisfy the requirements of subsection (b) above with respect to Qualified Service Organizations.

Substance Use Disorder means a cluster of cognitive, behavioral, and physiological symptoms indicating that the individual continues using the substance despite significant substance-related problems such as impaired control, social impairment, risky use, and pharmacological tolerance and withdrawal. For the purposes of this Policy, Substance Use Disorder does not include tobacco or caffeine use.

Third-party Payer means an individual or entity who pays and/or agrees to pay for Diagnosis or Treatment furnished to a patient on the basis of a contractual relationship with the patient or a member of the patient's family or on the basis of the patient's eligibility for federal, state, or local governmental benefits.

Treating Provider Relationship means that, regardless of whether there has been an actual in-person encounter: (a) a patient is, agrees to, or is legally required to be diagnosed, evaluated, and/or treated, or agrees to accept consultation, for any condition by an individual or entity, and; (b) the individual or entity undertakes or agrees to undertake Diagnosis, evaluation, and/or Treatment of the patient, or consultation with the patient, for any condition.

Treatment means the care of a patient suffering from a Substance Use Disorder, a condition which is identified as having been caused by the Substance Use Disorder, or both, in order to reduce or eliminate the adverse effects upon the patient.

Withdrawal Management means the use of pharmacotherapies to treat or attenuate the problematic signs and symptoms arising when heavy and/or prolonged substance use is reduced or discontinued.

PROCEDURE:

- 1. Notice to Patients.** At the time of admission to Lakeview Holdings or, in the case that a patient does not have capacity upon admission to understand his or her medical status, as soon thereafter as the patient attains such capacity, Lakeview Holdings shall (a) communicate to each patient that federal law and regulations protect the confidentiality of Substance Use Disorder patient records; and (b) give to each patient a summary in writing of the federal law and regulations. Refer to Attachment A, Sample Notice of Confidentiality of Substance Use Disorder Patient Records.
- 2. Identifying Patients.** Lakeview Holdings will acknowledge the presence of an identified patient in a facility or component of a facility which is publicly identified as a “Lakeview Holdings” only if the patient's written authorization is obtained or if an authorizing court order is entered, or other specific terms of this Policy permit a Disclosure of the information. Except as set forth below and in Sections 23 and 24, the patient’s written authorization must be obtained on the Authorization Form located on the last page of the Company policy Authorization for Uses and Disclosures of Protected Health Information, IP.PRI.010. Special terms apply to authorizations for disclosures to health information exchanges and other authorizations using general designations (as described in Section 22(d)(iv) below) to reference the recipients of Patient Identifying Information.
- 3. Communications Within a Program or Between a Program and An Entity Having Direct Administrative Control Over That Program.** Lakeview Holdings may Disclose Covered Information between or among personnel having a need for the information in connection with their duties that arise out of the Diagnosis, Treatment, or referral for Treatment of Substance Use Disorders, if communications are (a) within the Treatment program, or (b) between a Lakeview Holdings and an entity that has direct administrative management of Lakeview Holdings.
- 4. Responding to Requests.** In any case where Lakeview Holdings receives a request for Disclosure of Covered Information but where this Policy does not allow Disclosure, any Disclosure must be made in a way that will not affirmatively reveal that an identified individual has been, or is being, diagnosed or treated for a Substance Use Disorder. An inquiring party may be referred to 42 CFR Part 2 and advised that the regulations restrict the Disclosure of Substance Use Disorder patient records, but may not be told Upon receipt of a request for Covered Information that is not permitted under this Policy, refer

to Attachment A, Sample Notice of Confidentiality of Substance Use Disorder Patient Records, and either read or provide a copy of the Notice to the requestor.

5. **Qualified Service Organizations.** Lakeview Holdings may Disclose Covered Information to a Qualified Service Organization as necessary for the Qualified Service Organization to provide services to the Lakeview Holdings.
6. **FDA Standards.** Lakeview Holdings may Disclose Covered Information to medical personnel of the Food and Drug Administration (FDA) who assert a reason to believe that the health of any individual may be threatened by an error in the manufacture, labeling, or sale of a product under FDA jurisdiction, and that the information will be used for the exclusive purpose of notifying patients or their physicians of potential dangers. The Privacy Official shall be consulted prior to any Disclosure of information pursuant to this provision. Immediately following any Disclosure pursuant to this provision, the Lakeview Holdings shall document the Disclosure in the patient's records, setting forth in writing: (1) the name of the medical personnel to whom Disclosure was made and their affiliation with the FDA; (2) the name of the individual making the Disclosure; (3) the date and time of the Disclosure; and (4) The nature of the error.
7. **Crime on Premises/Against Personnel.** In the event of a crime or a threat to commit a crime on the premises of Lakeview Holdings or its respective departments, or against personnel of the Lakeview Holdings Program, Disclosure of Covered Information to law enforcement is permitted to the extent the information: (a) is directly related to a patient's commission of a crime on the premises of Lakeview Holdings or against personnel of the Lakeview Holdings or to a threat to commit such a crime; and (b) is limited to the circumstances of the incident, including the patient status of the individual committing or threatening to commit the crime, that individual's name and address, and that individual's last known whereabouts. The Privacy Official shall be consulted prior to any Disclosure of information pursuant to this provision.
8. **Child Abuse.** Lakeview Holdings may report incidents of suspected child abuse and neglect as required by and in accordance with state law. To the extent that state law mandates that a Lakeview Holdings provide relevant Covered Information to state or local governmental authorities, Covered Information may be provided. However, the restrictions under 42 CFR Part 2 continue to apply to the original patient records maintained by Lakeview Holdings

including Disclosure and use for civil or criminal proceedings which may arise out of the report of suspected child abuse and neglect. Accordingly, if, after a report is filed with relevant Covered Information, a subpoena for Covered Information is subsequently issued in connection with civil or criminal proceedings which arise from the report of suspected child abuse and neglect, the subpoena should be addressed in accordance with Section 15 of this Policy. The Privacy Official shall be consulted prior to any Disclosure of information pursuant to this provision. Questions regarding state law and the extent of Covered Information subject to Disclosure under state law relating to suspected child abuse and neglect shall be referred to the Privacy Official, who may consult with the Facility's assigned Operations Counsel.

9. **Medical Emergency.** Lakeview Holdings may Disclose Covered Information to medical personnel to the extent necessary to meet a bona fide medical emergency in which the patient's prior informed consent cannot be obtained. Immediately following Disclosure, the Disclosure must be documented in writing in the patient's records, setting forth (a) the name of the medical personnel to whom Disclosure was made and their affiliation with any health care facility, (b) the name of the individual making the Disclosure, (c) the date and time of Disclosure, and (d) the nature of the emergency.

10. **Research.** Company Affiliates or their respective departments may Disclose Covered Information to qualified personnel for the purpose of conducting scientific research, if the Program Director (in consultation with the Privacy Official) makes a determination that:

(a) The recipient is a HIPAA-covered entity or business associate, and has obtained and documented authorization from the patient, or a waiver or alteration of authorization, consistent with the HIPAA Privacy Rule at 45 CFR 164.508 or 164.512(i), as applicable; or

(b) The recipient is subject to the HHS regulations regarding the protection of human subjects (45 CFR part 46), and has either provided documentation that the researcher is in compliance with the requirements of the HHS regulations, including the requirements related to informed consent, or a has provided a waiver of consent (45 CFR 46.111 and 46.116) or that the research qualifies for exemption under the HHS regulations (45 CFR 46.101(b) and any successor regulations; or

(c) If the recipient is both a HIPAA covered entity or business associate and is subject to the HHS regulations regarding the protection of human subjects, the recipient must meet the requirements of subsection (a) and (b) above.

For any Disclosures pursuant to this Section 10, the recipient (i) is fully bound by the regulations under 42 CFR Part 2 and, if necessary, must resist in judicial proceedings any efforts to obtain access to patient records except as permitted by the regulations in this part; (ii) must not re-disclose Patient Identifying Information except back to the individual or entity from whom that Patient Identifying Information was obtained or as otherwise permitted by law; (iii) may include Covered Information in research reports only in aggregate form in which Patient Identifying Information has been rendered non-identifiable such that the information cannot be re-identified and serve as an unauthorized means to identify a patient, directly or indirectly, as having or having had a Substance Use Disorder; (iv) must maintain and destroy Patient Identifying Information in accordance with the security policies and procedures established by the recipient in accordance with 42 CFR § 2.16; and (v) must retain records in compliance with applicable federal, state, and local record retention laws.

Because a limited data set (as described under 45 CFR §164.514(e)) may include Patient Identifying Information, unless otherwise directed by the Privacy Official, limited data sets with Covered Information will not be disclosed for research purposes unless the requirements of this Section 10 are satisfied.

Any individual or entity conducting scientific research using Patient Identifying Information obtained under this Section 10 that requests linkages to data sets from data repositories holding Patient Identifying Information must:

a) Have the request reviewed and approved by an Institutional Review Board (IRB) registered with the Department of Health and Human Services, Office for Human Research Protections in accordance with 45 CFR part 46 to ensure that patient privacy is considered and the need for identifiable data is justified. Upon request, the researcher may be required to provide evidence of the IRB approval of the research project that contains the data linkage component.

11. Special Audit and Evaluation Activities/No Records Copied or Removed.

If Lakeview Holdings has not downloaded, copied or removed from the premises of the Lakeview Holdings nor forwarded electronically to another electronic system or device, Covered Information may be Disclosed in the course of a review of records on the premises of a Lakeview Holdings to any Special A/E Personnel. Special A/E Personnel receiving the Covered Information under this provision must agree in writing not to Disclose any Covered Information to any third party, except as described in Section 14 below, and must agree to use the Covered Information only to carry out the audit or evaluation purpose or to investigate or prosecute criminal or other activities, as authorized by an appropriate court order. The Privacy Official shall be consulted prior to any Disclosure of information pursuant to this provision.

12. Special Audit and Evaluation Activities/Copies or Records Removed.

Records containing Covered Information may be copied or removed from the premises of the Lakeview Holdings, or downloaded or forwarded to another electronic system or device from the Lakeview Holdings electronic records by Special A/E Personnel (meeting the criteria of subsection (a) of the definition of Special A/E Personnel above) who agree in writing to:

(a) maintain and destroy the Patient Identifying Information a manner consistent with the policies and procedures established under 42 CFR §2.16, which policies and procedures must address: (i) paper records, including standards for: transferring and removing such records; destroying such

records, including sanitizing the hard copy media associated with the paper printouts, to render the Patient Identifying Information non-retrievable; maintaining such records in a secure room, locked file cabinet, safe, or other similar container, or storage facility when not in use; using and accessing workstations, secure rooms, locked file cabinets, safes, or other similar containers, and storage facilities that use or store such information; and rendering Patient Identifying Information non-identifiable in a manner that creates a very low risk of re-identification (*e.g.*, removing direct identifiers); and (ii) electronic records, including standards for: creating, receiving, maintaining, and transmitting such records; destroying such records, including sanitizing the electronic media on which such records are stored, to render the Patient Identifying Information non-retrievable; using and accessing electronic records or other electronic media containing Patient Identifying Information; and rendering the Patient Identifying Information non-identifiable in a manner that creates a very low risk of re-identification (*e.g.*, removing direct identifiers).

(b) retain records in compliance with applicable federal, state and local retention laws;

(c) not Disclose any Covered Information to any third party except as described in Section 14 below; and

(d) use the Covered Information only to carry out the audit or evaluation purpose or to investigate or prosecute criminal or other activities, as authorized by an appropriate court order.

13. The Privacy Official shall be consulted prior to any Disclosure of information pursuant to this provision.

14. **Third Party Payers.** For information covered by this Policy, written authorization must be obtained prior to release of information to third party payers. For any period for which the Program Director determines that a patient, other than a Minor or one who has been adjudicated incompetent, suffers from a medical condition that prevents knowing or effective action on his or her own behalf, the Program Director may exercise the right of the patient to consent to a Disclosure for the sole purpose of obtaining payment for services from a third party payer. At the time of admission or as soon thereafter as possible, each Lakeview Holdings should seek to obtain written consent/authorization for Disclosures for billing and payment purposes. Disclosures to agents of Third Party Payers (which may include agents engaged by Third Party Payers for audit purposes) may be permitted where Attachment B, Consent for Disclosure of Information for Treatment and Billing/Payment, has been executed, but the Third Party Payer should provide written documentation of the agency relationship in advance of sharing of Covered Information. Refer to Attachment B, Consent for Disclosure of Information for Treatment and Billing/Payment.

15. **Multiple Enrollments.** Lakeview Holdings may make certain Disclosures of Covered Information for purposes of preventing multiple enrollments in Withdrawal Management and Maintenance Treatment programs, and may make certain Disclosures to the criminal justice system where the patient was required to obtain Treatment at the facility/department as a condition of the patient's disposition in a criminal proceeding, parole or release from custody. The Privacy Official shall be consulted prior to any Disclosure of information pursuant to this provision.

16. **Deceased Patients.** Lakeview Holdings may Disclose Covered Information relating to the cause of death of a patient to the extent required by laws relating to the collection of death statistics/information or other vital statistics or permitting inquiry into the cause of death. Any other Disclosure of information identifying a deceased patient as having a Substance Use Disorder is subject to this Policy and if a written authorization to the Disclosure is required, that authorization may be given by an executor, administrator, or other personal representative appointed under applicable state law. If there is no such appointment, the authorization may be provided by the patient's spouse or, if none, by other family member authorized under state law, subject to the Company's other policies relating to Disclosure of protected health information. Questions regarding the status or authority of an individual as executor, administrator or other individual under state law should be referred to the facility's assigned Operations Counsel.

17. **Notice to Accompany Disclosure.** Each Disclosure made with the patient's written consent must be accompanied by the following written statement:

This information has been disclosed to you from records protected by federal confidentiality rules (42 CFR part 2). The federal rules prohibit you from making any further disclosure of information in this record that identifies a patient as having or having had a substance use disorder either directly, by reference to publicly available information, or through verification of such identification by another person unless further disclosure is expressly permitted by the written consent of the individual whose information is being disclosed or as otherwise permitted by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose (see § 2.31). The federal rules restrict any use of the information to investigate or prosecute with regard to a crime any patient with a substance use disorder, except as provided at §§ 2.12(c)(5) and 2.65.

18. **Consent/Authorization.** Except as set forth above, Disclosures of Covered Information require appropriate written consent/authorization. A written consent/authorization to a Disclosure under this Policy may be paper or electronic and must include:

- (a) The name of the patient.
- (b) The specific name(s) or general designation(s) of the Lakeview Holdings(s), entity(ies), or individual(s) permitted to make the Disclosure.

- (c) How much and what kind of information is to be Disclosed, including an explicit description of the Substance Use Disorder information that may be Disclosed.
- (d) (i) The name(s) of the individual(s) to whom a Disclosure is to be made; or
 - (ii) If the recipient entity has a Treating Provider Relationship with the patient whose information is being Disclosed, such as a hospital, a health care clinic, or a private practice, the consent/authorization must include the name of that entity; or
- (e) A statement that the consent/authorization is subject to revocation at any time except to the extent that Lakeview Holdings or other lawful holder of Patient Identifying Information that is permitted to make the Disclosure has already acted in reliance on it. Acting in reliance includes the provision of Treatment services in reliance on a valid consent to Disclose information to a third- party payer.
- (f) The date, event, or condition upon which the consent/authorization will expire if not revoked before. This date, event, or condition must ensure that the consent/authorization will last no longer than reasonably necessary to serve the purpose for which it is provided.
- (g) The signature of the patient and, when required for a patient who is a Minor, the signature of an individual authorized to sign the consent/authorization as described above; or, when required for a patient who is incompetent or deceased, the signature of an individual authorized to sign for the incompetent or deceased patient as described above. Electronic signatures are permitted to the extent that they are not prohibited by any applicable law.
- (h) The date on which the consent is signed.

For uses and Disclosures that require authorization under HIPAA, the consent/authorization must also meet all requirements for a valid authorization under the Company's HIPAA policies and procedures.

19. **Consent for Disclosures to Healthcare Providers for Treatment.** While the regulations under 42 CFR Part 2 include provisions addressing uses of Covered Information within a Lakeview Holdings and Disclosures in medical emergencies, subject to the terms and requirements above, many Disclosures of Covered Information to healthcare providers outside of the Lakeview Holdings, even for Treatment purposes, will require appropriate consent. At the time of admission or as soon thereafter as possible, each Lakeview Holdings should seek to obtain written consent/authorization for Disclosures for Treatment purposes. Refer to Attachment B, Consent for Use and Disclosure of Information for Treatment and Billing/Payment.

20. **Family Members/Friends/Others Involved in Patient's Care.** The regulations under 42 CFR Part 2 **do not** include any exceptions specifically for Disclosures of Covered Information to family members, close friends or others identified by the Covered Patient. Accordingly, unless otherwise expressly permitted by this Policy, Covered Information should not be Disclosed to family members, friends or others who might otherwise be considered involved in a patient's care. For example, even if a Covered Patient has provided a password or has provided verbal consent to a Disclosure to a spouse, except as otherwise expressly permitted by this Policy (*e.g.*, provisions relating to incapacitated adult patients, deceased patients, etc.), Covered Information should not be Disclosed to the spouse unless an appropriate consent/authorization meeting the standards set forth below has been executed naming the spouse. As family members, friends and/or others identified by the Covered Patient may be involved in therapy sessions and planning for post-discharge care, among other activities, at the time of admission or as soon thereafter as possible, each Lakeview Holdings should seek to obtain written consent/authorization for Disclosures to appropriate family members, friends and/or others identified by the Covered Patient who may need Covered Information in connection with care. Refer to Attachment C, Consent For Disclosure to Family/Friends.

21. **List of Disclosures.** Upon request, Covered Patients who have consented to Disclose their Patient Identifying Information using a general designation (as described under Section 22 of this Policy) must be provided a list of entities to which their information has been Disclosed pursuant to the general designation. Patient requests for lists of General Designation Disclosures under this Section 25: (a) must be made in writing; and (b) are limited to General Designation Disclosures made within the past two years prior to the request. If a request for a list of General Designation Disclosures is received, Lakeview Holdings will:

(i) respond in 30 or fewer days of receipt of the written request; and (ii) for each General Designation Disclosure made within the two years prior to the request, provide the name(s) of the entity(ies) to which the General Designation Disclosure was made, the date of the General Designation Disclosure, and a brief description of the Patient Identifying Information Disclosed.

ATTACHMENT A

Confidentiality of Substance Use Disorder Patient Records

The confidentiality of Substance Use Disorder patient records maintained by this program is protected by federal law and regulations. Generally, the program may not say to a person outside the program that a patient attends the program, or disclose any information identifying a patient as having a substance use disorder unless:

- (1) The patient or an authorized representative consents in writing;
- (2) The disclosure is allowed by a court order; or
- (3) The disclosure is made to medical personnel in a medical emergency or to qualified personnel for research, audit, or program evaluation.

Violation of the federal law and regulations by a program is a crime. Suspected violations may be reported, consistent with federal regulations, to: Executive Office for United States Attorneys, United States Department of Justice, 950 Pennsylvania Avenue, NW, Room 2242, Washington, DC 20530-0001 or to the Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Substance Abuse Treatment (CSAT), 5600 Fishers Lane, Rockville, MD 20857.

Federal law and regulations do not protect any information about a crime committed by a patient either at the program or against any person who works for the program or about any threat to commit such a crime.

Federal laws and regulations do not protect any information about suspected child abuse or neglect from being reported under state law to appropriate state or local authorities.

See 42 U.S.C. 290dd-3 and 42 U.S.C. 290ee-3 for federal laws and 42 CFR part 2 for federal regulations.

